| Identification | More | [Name]
DL-PENICILLAMINE | [CAS]
52-66-4 | [Synonyms]
3,3-DIMENTHYL-DL-CYSTEINE
3,3-DIMETHYL-DL-CYSTEINE
AKOS NCG1-0051
BETA, BETA-DIMETHYL-DL-CYSTEINE
BETA-MERCAPTO-DL-VALINE
DL-2-AMINO-3-MERCAPTO-3-METHYLBUTANOIC ACID
DL-BETA,BETA-DIMETHYLCYSTEINE
DL-BETA-MERCAPTOVALINE
DL-PENICILLAMINE
PENICILLAMINE
PENICILLAMINE(DL-)
3-mercapto-dl-valin
3-mercapto-dl-valine
dl-3-mercaptovaline
dl-valin
3,3-Dimethyl-DL-cysteine~3-Mercapto-DL-valine
DL-PENICILLAMINE, 99+%
DL-PENICILLAMINE, 98+%
β,β-dimethyl-dl-cysteine
DL-PENCILLAMINE | [EINECS(EC#)]
200-147-2 | [Molecular Formula]
C5H11NO2S | [MDL Number]
MFCD00004856 | [Molecular Weight]
149.21 | [MOL File]
52-66-4.mol |
| Chemical Properties | Back Directory | [Appearance]
white to almost white crystalline powder | [Melting point ]
204-208 °C(lit.)
| [Boiling point ]
251.8±35.0℃ (760 Torr) | [density ]
1.204±0.06 g/cm3 (20 ºC 760 Torr) | [refractive index ]
1.5216 (estimate) | [Fp ]
106.1±25.9℃ | [storage temp. ]
2-8°C
| [solubility ]
Methanol (Slightly), Water (Soluble) | [form ]
solid | [pka]
pK: 1.8 (carboxyl); 7.9 (a-amino); 10.5 (b-thiol) | [Water Solubility ]
Soluble in ethanol, hot water and sodium hydroxide. | [Merck ]
14,7088 | [BRN ]
2039817 | [CAS DataBase Reference]
52-66-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin .
R40:Limited evidence of a carcinogenic effect.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing .
S22:Do not breathe dust . | [WGK Germany ]
3
| [RTECS ]
YV9445000
| [HS Code ]
29309099 | [Toxicity]
LD50 orally in rats: 365 mg/kg (Jaffe) |
| Hazard Information | Back Directory | [Chemical Properties]
white to almost white crystalline powder | [Uses]
antirheumatic,
chelating agent (copper),
Wilson's desease treatment | [Definition]
ChEBI: An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group. | [Safety Profile]
Poison by ingestion and intraperitoneal routes. Mutation data reported. When heated to decomposition it emits toxic fumes of SOx and NOx. | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Application in Rheumatic Arthritis]
Penicillamine onset may be seen in 1 to 3 months, and most responses occur within 6 months. Early adverse effects include skin rash, metallic taste, hypogeusia, stomatitis, anorexia, nausea, vomiting, and dyspepsia. Glomerulonephritis may occur, which manifests as proteinuria and hematuria. Penicillamine is usually reserved for patients who are resistant to other therapies because of the rare but potentially serious induction of autoimmune diseases (e.g., Goodpasture’s syndrome, myasthenia gravis).
|
|
|